Kornimate/medical-research-clean huggingface dataset:
effects of aquamin f on nsaid dose reduction in osteoarthritis of the knee

Conditions: Osteoarthritis of the Knee

Summary: the objective of this trial is to evaluate the effect of aquamin f versus placebo on nsaid (non-steroidal anti-inflammatory drug) dose reduction in subjects with osteoarthritis of the knee. hypothesis 1: after 12 weeks of treatment, subjects taking aquamin f will use significantly less nsaid medications for symptoms of osteoarthritis versus placebo alone. hypothesis 2: no significant differences will be seen for adverse events between the subjects taking aquamin f or placebo.


Eligibility criteria:
inclusion criteria: * subjects aged 35 to 75, male or female * subjects diagnosed with symptomatic moderate to severe osteoarthritis of the knee according to the modified criteria of the american college of rheumatology 17,18 * subjects who present with osteoarthritis of the knee as judged by symptoms and disabilities detectable through published, validated questionnaires or previous diagnosis by a physician * subjects who are symptomatic with daily or near daily pain and stiffness from osteoarthritis * subjects who are taking non-steroidal anti-inflammatory drugs (nsaids) prior to study enrollment * subjects who are willing to stop nsaids and use acetaminophen for pain management during the trial * subjects with screening womac osteoarthritis index total score (transformed score) of not more than 75 * subjects with ability to comprehend and complete the questionnaires and forms * subjects whose schedules permit clinical evaluations every four weeks * subjects who are willing to stop taking calcium supplements, if any and to restrict consumption of high calcium food to 600mg (two dairy servings) per day * subjects with a high probability of compliance with study procedures and test article consumption * subjects willing and able to follow protocol guidelines and schedules and complete diaries * subjects who are likely to abstain from taking unathorized supplements or participating in any other clinical trial or experimental treatment during this trial * subjects with normal gastrointestinal digestion and absorption exclusion criteria: * subjects who have a history of inflammatory arthritis, gout, pseudogout, paget's disease, seizure disorder, insulin dependent diabetes mellitus, uncontrolled hypertension, unstable cardiovascular disease, active hepatic or renal disease, active cancer and/or hiv infection * subjects who are non-ambulatory or bedridden due to osteoarthritis * subjects who are dependent on prescription drugs to control pain * subjects on any other clinical trial or experimental treatment in the past 3 months * subjects who are pregnant, lactating or at risk of becoming pregnant * subjects who have received : intramuscular corticosteroid injection or systemic corticosteroid administration within 4 weeks prior to study enrollment, intra-articular corticosteroid injection within 2 months prior to study enrollment or intra-articular hyaluronic acid injection within 4 months prior to study enrollment.

Keywords: osteoarthritis clinical trial aquamin f nsaid
propacetamol to reduce post cesarean section uterine contraction pain

Conditions: Uterine Pain

Summary: to evaluate that perioperative regular usage of propacetamol to reduce post cesarean section uterine contraction pain and opioid consumption

the most common method of pain control after cesarean section is intravenous patient-control analgesia (ivpca) with morphine. multimodal analgesia could improve the quality of perioperative pain control and reduceside effects of opioids. previous researches marked that perioperative pain after cesarean section includes somatic wound pain and visceral uterine contraction pain. according to academy of breastfeeding medicine, propacetamol is a safe pain-killer for an expectant mother and almost free from breast milk after intravenous injection. this study is a prospective double-blind randomized-controlled trial to evaluate that propacetamol could reduce visceral uterine contraction pain after cesarean section. post cesarean section women will divide into three groups: 1. pain control with ivpca for 2 days 2. pain control with ivpca and propacetamol 1g every 6 hours for 2 days 3. pain control with ivpca and propacetamol 2g every 6 hours for 2 days

Eligibility criteria:
inclusion criteria: * pregnancy more than 36 weeks which is expected to receive caesarean section * post caesarean section woman, age greater than or equal to 20 years old * asa physical status class 1 or 2 exclusion criteria: * asa physical status class 3 or above * less than 20 years old * past caesarean section for longitudinal wounds * undergone major abdominal surgery * chronic pain * allergic to morphine or propacetamol * liver dysfunction * treatment with anticoagulant * emergency operation

Keywords: cesarean section uterine contraction pain propacetamol
study of secukinumab compared to fumaderm® in adults with moderate to severe psoriasis.

Conditions: Psoriasis

Summary: this is a randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to fumaderm®, in 200 adults with moderate to severe plaque type psoriasis who are candidates for systemic therapy. the study consists of 2 periods: a screening period of at least one week and up to four weeks, and a treatment period of 24 weeks. during the screening period eligibility of the patients is confirmed. eligible patients are randomized 1:1 to treatment arm a or b at week 0. patients in treatment arm a receive secukinumab administered at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20 and are followed up for assessments of the study endpoints until week 24. patients in treatment arm b receive daily doses of fumaderm® p.o.. safety and efficacy measurements of secukinumab and fumaderm® will be performed throughout the study and up to week 24.


Eligibility criteria:
inclusion criteria: * men or women must be at least 18 years of age at the time of screening * chronic plaque-type psoriasis diagnosed for at least 6 months before randomization patients with moderate to severe plaque psoriasis who are candidates for systemic therapy as defined at randomization by: * pasi score of \>10 * affected body surface area (bsa) \> 10% * dlqi \>10 * inadequate response, intolerance or contraindication to topical psoriasis treatment as documented in the patient's medical history or reported by the patient or determined by the investigator at screening. exclusion criteria (abbreviated): * previous systemic treatment of plaque psoriasis or known contraindication for systemic therapy at baseline * ongoing use of other prohibited psoriasis and non-psoriasis treatment. * clinically important active infections or infestations, chronic, recurrent or latent infections or infestations * patients with severe liver diseases * patients with severe gastrointestinal diseases including but not limited to ventricular and duodenal ulcers * patients with severe kidney diseases or serum creatinine above 1 x uln * patients with known hematological disease or lab abnormalities * pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of contraception (if necessary)
pharmacists provide telemedicine in addition to clinic visits to improve diabetes management

Conditions: Telemedicine

Summary: this prospective study will include both an intervention and control arm. the control arm will receive face-to-face pharmacy clinic visits per standard of care. the intervention arm will receive pharmacy clinic visits plus additional telephone follow-up. patients with a hemoglobin a1c in the last 3 months greater than 9% will be eligible. eligible patients must have a primary care physician at johns hopkins outpatient center (jhoc) or east baltimore medical center (ebmc). purpose: to compare the change in hemoglobin a1c over the 3 month study period in the intervention group in which patients participate in telemedicine, to a control group in which they do not


Eligibility criteria:
inclusion criteria: * adult patients with a primary care provider at jhoc or embc * patients have seen primary care provider within last 6 months * patients with hemoglobin a1c greater than 9% exclusion criteria: * patients \<18 years of age * patients with previously established care with jhh ambulatory care pharmacist * patients with communication barriers who do not have a caregiver * patients with new diagnosis of diabetes * patients who are pregnant or planning to become pregnant during the time of the study * patients followed by endocrinology or diabetes center
secondary prevention of depression applying an experimental attentional bias modification procedure

Conditions: Major Depression

Summary: depression (major depressive disorder; mdd) has been dubbed "the common cold among the mental illnesses" and it is also a highly recurrent disorder. secondary prevention has been identified as a key goal in the long-term management of depression. high recurrence rate suggests that there are specific vulnerability factors that increase people's risk for developing repeated episodes of the disorder. preventive strategies should identify and ameliorate these factors to reduce the individual's risk of subsequent episodes. biased attention for emotional stimuli is central to the cognitive model where increased sensitivity to negative cues is believed to fuel the negative thoughts and feelings in depression and play a key role in maintaining the illness. selective biases in attention can be modified by a simple computerized technique; the attention bias modification task (abm). this project aims to investigate whether abm can reduce surrogate and clinical markers of relapse in a large group highly vulnerable to depressive episodes. the effects of abm, immediately after the two weeks intervention, on three key risk factors for depression will be studied: residual symptoms, cortisol awakening response and emotion regulation strategies. the participants will be followed up after 1 month, 6 months and 12 months. the hypothesis that abm will reduce subsequent episodes of low mood over the following 12 months in this group in a manner predicted by early changes in these risk factors will be investigated. it will also be tested if such effects in the lab may be dependent on candidate genes which affect serotonin reuptake and which have been implicated in malleability and emotional learning. effects on underlying neural correlates of emotion regulation will be studied in an fmri experiment in a sub-sample and which will also be stratified by serotonin transporter genotype (see also nct02931487). the predictive value of meta cognitions related to rumination and the possible mediating effects of automatic thoughts and perceived stress will also be investigated in a sub group (see also nct02648165). the characterization of the cognitive, genetic and neural mechanisms underlying the abm effect will have key implications for future treatment development and combination with other treatment modalities like pharmacotherapy.


Eligibility criteria:
inclusion criteria: * nondepressed subjects (based on the mini structured interview) with a history of major depression exclusion criteria: * current or past neurological illness, bipolar disorder, psychosis or drug addiction.
7 days vs. 14 days of vonoprazan-based triple therapy for h. pylori eradication

Conditions: Helicobacter Pylori Infection; Gastritis; Vonoprazan; Adolescents

Summary: the study aims to test the efficacy of 7 days vs. 14 days of vonoprazan-triple therapy in the eradication of helicobacter pylori infection in adolescents and young children.

after being informed about the study details, all eligible participants (or their legal guardians) will give informed written consent to be involved. after a one week screening, eligible participants will be randomized to vonoprazan plus amoxicillin plus clarithromycin triple therapy for either 14 days (group 1), or 7 days (group 2) at a 1:1 ratio. after the end of therapy, h. pylori eradication will be evaluated after 4 weeks.

Eligibility criteria:
inclusion criteria: 1. participants in the age group (10-18 years), both genders, referred with dyspeptic complaints such as heartburn, dyspepsia, nausea, and epigastric pain who are positive for h. pylori infection by a standardized diagnostic test. 2. pediatric patients with a clinical, laboratory, and endoscopic diagnosis of h.p.-positive gastritis and the other conditions necessary for h.p. eradication, according to the maastricht v consensus report . exclusion criteria: 1. allergy to any of the drugs used in the study 2. previous attempts to eradicate h.p. 3. receipt of antibiotics, ppis, bismuth, h2 antagonists or probiotics within 4 weeks of the study. 4. children with the diagnosis of any condition that might affect the absorption of drugs such as celiac disease or crohn's disease. 5. hepatic impairment or kidney failure. 6. symptoms suggestive of functional disorders.

Keywords: helicobacter pylori vonoprazan triple therapy adolescent eradication rate children
comparison of bottle and cup feeding on transition to full breastfeeding and discharge time

Conditions: Preterm; Feeding, Bottle; Feeding Behavior; Feeding, Breast

Summary: breastfeeding is the ideal feeding method and that in the absence of breastfeeding the bottle and cup feeding are common alternatives. there is a lack of evidence regarding superiority of either of these methods. this study aimed to evaluate bottle feeding and cup feeding in preterm infants on the outcomes of full breastfeeding and discharge time.

an estimated 20 million infants are born preterm each year (\>37 weeks) and this number is increasing. the preterm newborn population is potentially unable to be fed orally for a long time in the postnatal period.however, it is not a disease that preterm infants cannot be fed orally as soon as they are born. since the physiological functions are not yet fully mature, their adaptation to the external uterine environment is more complicated.this situation also means a long hospital stay. therefore, the american academy of pediatrics (aap) has determined oral feeding of the preterm baby as the main criterion for discharge. in preterm infants, sucking and swallowing coordination occurs in the 32 to 34 gestation weeks.oral feeding skills are developed by applying various sensorimotor interventions and cue-based feeding protocols to increase oral feeding performance.tube feeding (orogastric and nasogastric) is widely preferred as their oral-motor skills are still immature.as postnatal age increases, alternative oral feeding methods are often used along with tube feeding.bottle feeding, cup feeding spoon feeding and syringe feeding are the most popular methods in clinical practice. while determining the most available method of oral feeding in preterm infants, the selection criteria include their capacity to facilitate the transition to full breastfeeding to help sustain breastfeeding to shorten the duration of hospitalization and to ensure sufficient nutrition. direct full breastfeeding is the important and most recommended feeding method in new-borns. however, since full breastfeeding is not immediately possible in preterm infants, they definitely need an alternative feeding method.

Eligibility criteria:
inclusion criteria: * preterm infants (30-34 weeks); * considered medically stable * with no facial deformity, * absent of neurological or congenital anomalies, * did not require sedation or vasoactive drugs * mother is providing breast milk \& plans to breastfeed. exclusion criteria: * presence of gastrointestinal conditions that complicate feeding such as nec, * absence of mother, * absence of breast milk, and * preterm infants fed only formula

Keywords: preterm infants bottle feeding cup feeding feeding methods breastfeeding
timed interval measurement of eotaxin in stroke study

Conditions: Stroke, Acute

Summary: stroke is caused by sudden changes in blood flow in the brain. this can be fatal or can result in permanent disability. a fast diagnosis is essential to initiate effective interventions and optimize benefits to patients. there are other diseases that can look like a stroke and these are called "stroke mimics". the quicker that stroke mimics can be ruled out the faster a stroke can be diagnosed and treatment can be given. the investigators may be able to use chemicals in the blood to rapidly confirm that a person has had a stroke. one such chemical is called eotaxin. eotaxin has been found to be changed in sufferers of a stroke but not in those with stroke mimics. however, more research is needed to confirm the usefulness of eotaxin. this feasibility study aims to provide the foundations to allow a large scale trial of this test. the study aims to recruit participants that have had a stroke or a stroke mimic from the acute stroke unit and stroke clinic at the royal devon and exeter hospital. up to 6 blood samples will be taken from each participant at different times over one week. eotaxin will be measured in these samples and in participant's leftover samples taken for clinical care. this is needed because the investigators know that the amount of eotaxin changes in the blood after a stroke but we do not know how quickly this change happens and for how long the change occurs. the study will also allow the investigators to understand how many participants will be needed for a large scale trial and the challenges that may be faced in recruiting participants.


Eligibility criteria:
inclusion criteria: * presenting with focal neurological symptoms suggestive of stroke * aged over 18 years exclusion criteria: * presenting later than 12 hours after symptom onset * under 18 years of age * history of cardiovascular disease (healthy controls) * history of neurological disease (healthy controls) * history of stroke mimics (healthy controls)
sing for your saunter part 2 r33

Conditions: Parkinson Disease

Summary: the goal of this clinical trial is to compare to rhythm-based walking interventions to enhance gait in people with parkinson's disease. the main questions it aims to answer are: * how does rhythm-based training influence walking performance? * how does brain activity change following rhythm-based training? participants will perform walking to music and walking while singing, and will train on the use of these rhythms for 12 weeks. the investigators will compare the effects of training with music to training with singing.


Eligibility criteria:
inclusion criteria: 1. at least 30 years of age 2. diagnosis of idiopathic, typical parkinson disease according to the uk brain bank criteria 3. hoehn \& yahr stages 2-3 (mild to moderate disease severity) 4. evidence of walking impairment (score at least 1 on gait item of mds_updrs) 4) stable on all parkinson disease medications for at least 2 months prior to study entry 5) willing and able to provide informed consent 6) right-handed exclusion criteria: 1. diagnosis of any other neurological condition 2. a score of 2 or greater on item # 3 on the freezing of gait questionnaire 3. significant cognitive impairment 4. unstable medical or concomitant illnesses or psychiatric conditions which, in the opinion of the investigators, would preclude successful participation 5. cardiac problems that interfere with ability to safely participate 6. orthopedic problems in the lower extremities or spine that may limit walking 7. contraindications for magnetic resonance imaging 8. unable to walk for 10 continuous minutes independently 9. left-handed 10. uncontrolled tremor or dyskinesia
evaluation of inter-reader reliability using images from subjects with alzheimer's disease (ad) or mild cognitive impairment (mci)

Conditions: Alzheimer's Disease

Summary: re-read of brain amyloid scans acquired in previous av-45 clinical studies by readers trained using updated reading methodology. the scans in this study came from subjects who had alzheimer's disease (ad) or mild cognitive impairment (mci).


Eligibility criteria:
participants: * inclusion criteria ad: * male or female \>=50 years of age * meet national institute of neurological and communicative disorders and stroke (nincds) criteria for probable ad with mini-mental state examination (mmse) score of 10-24 * inclusion criteria mci: * male or female \>=50 years of age * have a clinical dementia rating (cdr) of 0.5 * mmse \>24 * exclusion criteria: * have a history or current diagnosis of other neurologic disease * have had or currently have a diagnosis of other neurodegenerative disease * have participated in experimental therapy targeted to amyloid plaque readers: •private nuclear medicine physicians with no prior training in reading florbetapir-pet scans

Keywords: amyloid imaging positron emission tomography 18f-av-45 florbetapir f 18 diagnostic imaging
engraftment syndrome after autologous stem cell transplant: retrospective review in patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: engraftment syndrome after autologous stem cell transplant: retrospective review in patients with multiple myeloma

a retrospective chart review series will be performed fpr subjects enrolled from 1/1/2006.

Eligibility criteria:
inclusion criteria: * patients with multiple myeloma, developing engraftment syndrome exclusion criteria: * patients with multiple myeloma, with no features of engraftment syndrome

Keywords: multiple myeloma, engraftment syndrome
aprepitant and ondansetron monotherapy or combination for postoperative nausea and vomiting in thyroid cancer

Conditions: Thyroid Cancer

Summary: the vast majority of patients treated prophylactically with "first-line" antiemetics in the 5-hydroxytryptamine (5-ht3) receptor antagonist class still have significant ponv. combination therapies with different pharmacologic bases have the potential to reduce the incidence of ponv. this study is a multicenter, three-arm, prospective study to evaluate the efficacy and safety of aprepitant and ondansetron, monotherapy or in combination, in the prevention of nausea and vomiting after surgery for thyroid cancer.

postoperative nausea and vomiting (ponv) is the most common complication after surgery, especially thyroidectomy, and the incidence of ponv can be as high as 80% without the administration of prophylactic antiemetics. currently, available prophylactic interventions for ponv, especially monotherapy, lack universal efficacy. combination therapy with a different pharmacologic basis has the potential to reduce the incidence of ponv. previous studies using various 5-ht3 receptor antagonists in combination with aprepitant have shown promising results in reducing the incidence of ponv. the present study is a multicenter, three-arm, prospective study designed to evaluate the efficacy and safety of aprepitant and ondansetron, alone or in combination, in the prevention of postoperative nausea and vomiting in thyroid cancer.

Eligibility criteria:
inclusion criteria: 1. patients aged 18-80 years; 2. voluntary enrollment in the study and signing the informed consent form; 3. diagnosed with thyroid cancer and needing surgical treatment; exclusion criteria: 1. patient has depression, history of chronic pain, insulin-dependent diabetes mellitus i or ii, history of severe vomiting; 2. history of prior thyroid or neck surgery; 3. cases in which surgery requiring sternotomy is anticipated; 4. history of long-term hormone use, period of immunosuppressive therapy; 5. pre-operative voice changes or laryngoscopic confirmation of vocal cord paralysis; 6. pregnant or breastfeeding patients; 7. patients who are allergic to any of the study medications; 8. patients who have received any sedative, hypnotic, anxiolytic, opioid, steroid or other antiemetic medication within 24 hours prior to the procedure; 9. patients taking or planning to take a combination of drugs such as rifampicin, carbamazepine, phenytoin or other drugs that strongly induce cyp3a4 activity; 10. patients with other malignant tumors; 11. patients with hypothyroidism; 12. participating or planning to participate in other clinical studies.